The Real-World Impact of PARP Inhibitor Maintenance Therapy in High Grade Serous Tubo-Ovarian and Peritoneal Cancers.

Median PFS for patients with upfront surgery was 37 months (95% CI: 1.481 to 72.50), while median PFS for patients who had interval debulking post neoadjuvant chemotherapy was 19 months but did not reach statistical significance ( p = 0.49) ( Figure 3 A).

also in 111,027 other papers

However, in the recently reported TRUST trial [ 29 ], upfront surgery showed significantly improved median PFS (22.2 months) and showed a trend toward longer overall survival (OS) (54 months), compared to neoadjuvant chemotherapy, followed by interval cytoreductive surgery (19.7 months and 48.3 months, respectively.

also in 53,322 other papers